CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS

Michael Peter Diamond, V Limmroth, F Barkhof, N Desem, G Tachas

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Fingerprint

Dive into the research topics of 'CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS'. Together they form a unique fingerprint.

Medicine & Life Sciences